Visiongain Ltd.

Pharma companies must implement strategic pricing assessments across global markets and product lifecycle phases in order to develop effective pricing policies.(Source: Business Insights) 8th Annual Pricing and Reimbursement Conference - USA

Pharmacoeconomics is an area that is increasing importance every year. Health Economics and Outcomes Research 2009 - Leaping the fourth hurdle to achieve pharmaceutical success - 4th - 5th June 2009, BSG Conference Centre, London, UK.

India has all the competitive advantages for conducting clinical trials. As the country is increasingly becoming a favored destination for clinical trials. Clinical Trials in Asia Summit 2009 - 18th - 20th May 2009, The Park, New Delhi, India.

Monoclonal antibodies in cancer therapy – significant commercial opportunities with developing technologies and innovative products – our new report explains prospects

Pharmacovigilance gaining in importance after Vioxx problems-our new report analyses post-marketing assessment from the present onwards-Pharmacovigilance has been expanding in recent years, as companies are required to monitor drug safety post launch

There is great demand for lower-cost biological drugs: commercial and regulatory developments will make biosimilars and follow-on biologics a success – our new report explains how- Revenues for biologic drugs reached approximately $125bn in 2008.

Visiongain is proud to announce the release of the brand new report "Stem Cell - World Analysis". Stem cells represent one of the most promising medical breakthroughs of all time, as our new market report explains.

Visiongain is proud to announce the release of the brand new report "The Global Multiple Sclerosis Market". The multiple sclerosis (MS) market has total global revenues of over $6bn in 2008.

Visiongain is proud to announce the release of the brand new report "Parkinson's Disease". In 2006, the global sales of PD therapeutics were $3.1bn up by 11% from $2.5bn in 2005.

Visiongain is proud to announce the release of the brand new report "Live Licensing & In-Life Testing".